Emergent BioSolutions Balance Sheet Health
Financial Health criteria checks 2/6
Emergent BioSolutions has a total shareholder equity of $649.3M and total debt of $860.2M, which brings its debt-to-equity ratio to 132.5%. Its total assets and total liabilities are $1.8B and $1.2B respectively.
Key information
132.5%
Debt to equity ratio
US$860.20m
Debt
Interest coverage ratio | n/a |
Cash | US$111.70m |
Equity | US$649.30m |
Total liabilities | US$1.17b |
Total assets | US$1.82b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ER4's short term assets ($679.5M) exceed its short term liabilities ($651.3M).
Long Term Liabilities: ER4's short term assets ($679.5M) exceed its long term liabilities ($522.6M).
Debt to Equity History and Analysis
Debt Level: ER4's net debt to equity ratio (115.3%) is considered high.
Reducing Debt: ER4's debt to equity ratio has increased from 78.6% to 132.5% over the past 5 years.
Debt Coverage: ER4's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ER4's interest payments on its debt are well covered by EBIT.